Be the first to like this
Idera Pharmaceuticals (NASDAQ: IDRA) bucked the biotech sell-off last month by gaining more than 20%. The company, which currently doesn't have any products on the market, is working on intriguing new cancer therapies for patients with specific genetic mutations. Idera Pharmaceuticals approach is intriguing and investors should soon know whether its most advanced drug, IMO 8400, is effective in at least one rare form of cancer. View the slideshow to learn more about Idera Pharmaceuticals and what's driving interest in its shares.